Acumen Pharmaceuticals, Inc.
News
(2)April 2026
Acumen advances drug ACU193 to Phase 3 with Eisai partnership after Phase 2 success
# 🧾 What This Document Is This is an **Annual Report to Security Holders (ARS)** from Acumen Pharmaceuticals. Think of it as the company's "year-in-review" magazine sent to its shareholders. It's not the official, super-detailed 10-K filed with the SEC, but a more digestible summary that usually g
ABOS shareholders vote on adding 10 million shares to equity plan
# 🧾 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)** for Acumen Pharmaceuticals. Think of it as an invitation and a voter's guide for the company's **2026 Annual Meeting of Stockholders**. It explains what will be voted on, provides background on the company's leaders and pa
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.